John P. Butler
CIK 1591467 · CEO and President · last filed 2026-03-05
John P. Butler is a CEO and President who has filed 53 SEC Form 4 insider transactions across 4 companies since 2013. The most recent filing shows the insider bought $86.6K of AKBA on Mar 5, 2026. Across all open-market trades the lifetime net is −$1.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.26M
4
53
-$1.02M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AKBA | CEO and President | 3,526,992 | $0.92 | $3.26M | -$999.1K | 36 | 2026-03-05 |
| Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Director | 47,824 | $1.30 | $62.2K | $32.1K | 9 | 2023-10-11 |
| KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Director | 20,000 | — | — | $0 | 2 | 2017-06-20 |
| Relypsa Inc (RLYP) Delisted | Director | 2,250 | — | — | -$57.7K | 6 | 2016-09-02 |
Recent Filings
53 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-05 | AKBA | Buy (P) | +69,270 | $86.6K | EDGAR |
| 2026-02-04 | AKBA | Mixed | −166,055 | -$227.3K | EDGAR |
| 2026-02-03 | AKBA | Grant (A) | +743,000 | $0 | EDGAR |
| 2025-03-04 | AKBA | Sell (S) | −46,409 | -$84.9K | EDGAR |
| 2025-02-04 | AKBA | Mixed | +556,750 | -$302.9K | EDGAR |
| 2024-03-01 | AKBA | Sell (S) | −46,570 | -$73.6K | EDGAR |
| 2024-02-29 | AKBA | Sell (S) | −37,733 | -$57.4K | EDGAR |
| 2024-02-02 | AKBA | Mixed | +557,011 | -$78.1K | EDGAR |
| 2023-10-11 | Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Mixed | −80,765 | $0 | EDGAR |
| 2023-06-15 | Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Mixed | +47,709 | -$40 | EDGAR |